Epidemiological features of hepatitis B in the Russian Arctic

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Hepatitis B is an urgent medical and social problem in Russia.

AIM: To determine the epidemiological features of the hepatitis B in the Russian Arctic.

MATERIALS AND METHODS: We carried out a retrospective analysis of the incidence of hepatitis B (acute and chronic forms) in 9 Russian Arctic regions, 3 subarctic regions (Khanty-Mansiysk Autonomous Okrug, Magadan Region, Kamchatka Territory) and Russian Federation in 1999–2019. We also studied the prevalence of chronic hepatitis B and vaccination data against hepatitis B in these territories.

RESULTS: From 1999 to 2019 the incidence of acute hepatitis B in three subarctic regions decreased 166 times (from 66.5 to 0.4 per 100 thousand population), in the Arctic zone of 74.5 times (from 29.8 to 0.4 per 100 thousand population) and 73 times in Russia (from 43.8 to 0.6). The incidence of chronic hepatitis forms in the same period in the Arctic zone decreased by 8.6 times (from 140.1 to 16.3), 5.8 times in the subarctic regions (from 116.6 to 20.0) and 5.7 times in Russia (from 96.3 to 16.8). In 2018, the results of the prevalence of chronic hepatitis B in the Arctic zone (697.3) was higher than in Russia by 98% (352.1) and higher in the subarctic regions by 67% (588.6). Timely coverage of hepatitis vaccination in children aged 12 months in the Russian Federation, the Arctic zone and the subarctic regions is maintained at a high level (more than 90%) from 2004 in 2019. Coverage of children by vaccination to 17 years inclusive and adults up to 35 years on these territories also exceeded 90%.

CONCLUSIONS: Vaccination against hepatitis B in the Russian Federation led to a significant decrease in the incidence of this infection in the Russian Arctic. High prevalence of infection indicates the need to continue the program of mass vaccination and the timely introduction of the first dose of vaccine newborns. To reduce the risk of cirrhosis and liver cancer, it is necessary to increase the availability of diagnosis of the disease and its possible outcomes in the Arctic regions and timely provision of antiviral treatment of all patients.

Full Text

Restricted Access

About the authors

Anastasia A. Fomicheva

National Medical Research Center of Phthisiopulmonology and Infectious Diseases

Email: anastasia.fomichova@yandex.ru
ORCID iD: 0000-0002-0625-0284
SPIN-code: 5281-1670

MD, Junior Research Associate

Russian Federation, 4 Build. 2 Dostoevskogo st., 127473, Moscow

Nikolay N. Pimenov

National Medical Research Center of Phthisiopulmonology and Infectious Diseases

Email: n.pimenov@mail.ru
ORCID iD: 0000-0002-6138-4330
SPIN-code: 2314-2076

MD, Cand. Sci. (Med.)

Russian Federation, MD, Junior Research Associate

Svetlana V. Komarova

National Medical Research Center of Phthisiopulmonology and Infectious Diseases

Email: komarova.056@yandex.ru
ORCID iD: 0000-0002-7681-5455
SPIN-code: 2810-3381

MD, Research Associate

Russian Federation, MD, Junior Research Associate

Aleksandr V. Urtikov

National Medical Research Center of Phthisiopulmonology and Infectious Diseases

Email: urtikovav@mail.ru
ORCID iD: 0000-0001-7319-0712
SPIN-code: 7260-6505

MD, Research Associate

Russian Federation, 4 Build. 2 Dostoevskogo st., 127473, Moscow

Olga A. Paevskaya

The First Sechenov Moscow State Medical University (Sechenov University)

Email: paevskaya_o_a@staff.sechenov.ru
ORCID iD: 0000-0003-4917-3992
SPIN-code: 7410-3130

MD, Cand. Sci. (Med.), Assistant Lecturer

Russian Federation, Moscow

Natalya N. Tsapkova

The First Sechenov Moscow State Medical University (Sechenov University)

Email: tsapkova.natali@yandex.ru
ORCID iD: 0000-0002-7823-9287
SPIN-code: 3734-7392

MD, Cand. Sci. (Med.), Associate Professor

Russian Federation, Moscow

Vladimir P. Chulanov

National Medical Research Center of Phthisiopulmonology and Infectious Diseases; The First Sechenov Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: ChulanovVP@nmrc.ru
ORCID iD: 0000-0001-6303-9293
SPIN-code: 2336-4545

MD, Dr. Sci. (Med.), Professor

Russian Federation, 4 Build. 2 Dostoevskogo st., 127473, Moscow; Moscow

References

  1. Lukin YF. Status, composition, population of the Russian Arctic. Arctic and North. 2014;(15):57–94. (In Russ).
  2. Fauzer VV, Smirnov AV. The world's arctic: natural resources, population distribution, economics. Arctic: Ecology and Economy. 2018;3(31):6–22. doi: 10.25283/2223-4594-2018-3-6-22
  3. Bruce M, Zulz T, Koch A. Surveillance of infectious diseases in the Arctic. Public Health. 2016;137:5–12. doi: 10.1016/j.puhe.2016.06.014
  4. Petrova PG, Borisova NV, Platonov FA, Turkebaeva LK. The role of field research in the study of public health in the Arctic. Bulletin of the Northeastern Federal University named after M.K. Ammosov. 2017;(2):4. (In Russ).
  5. Volova LU, Rodina EV. HIV epidemic situation among Small Indigenous Populations of Northeast Russia. J Infectology. 2014; 6(2):76–82. (In Russ).
  6. Toropushina EE. Estimation of the social in frastructure development in the North and the Arctic of Russia. EKO. 2016; (6):99–108. (In Russ).
  7. Zalyalov BA, Pimenov NN, Komarova SV, et al. Epidemiological features of hepatitis B and C in the Arctic Region. Epidemiology and Infectious Diseases. Current Items. 2019;9(1):81–92. (In Russ). doi: 10.18565/epidem.2019.1.81-92
  8. Petrova DP, Mindlina AY. Comparative analysis of the morbidity of respiratory infections in the Arctic Zone and other Territories of Russia. Epidemiology and Vaccinal Prevention. 2020;19(4): 48–56. (In Russ). doi: 10.31631/2073-3046-2020-19-4-48-56
  9. Osiowy C, Simons BC, Rempel JD. Distribution of viral hepatitis in indigenous populations of North America and the circumpolar Arctic. Antivir Ther. 2013;18(3 Pt B):467–473. doi: 10.3851/IMP2597
  10. Sleptsova SS. Parenteral viral hepatitis and their outcomes in the Republic of Sakha (Yakutia). Moscow: Chekhovskii Pechatnyi Dvor; 2017. 216 р. (In Russ).
  11. Semenov SI, Savvin RG, Krivoshapkin VG, et al. Epidemiological characteristics of hepatitis with parenteral transmission mechanism of pathogens in Yakutia. Far Eastern Journal of Infectious Pathology. 2004;(5):20–23. (In Russ).
  12. Ohba K, Mizokami M, Kato T, et al. Seroprevalence of hepatitis B virus, hepatitis C virus and GB virus-C infections in Siberia. Epidemiol Infect. 1999;122(1):139–143. doi: 10.1017/s0950268898001940
  13. Bugaeva TT, Alexeeva MN, Ivanov PM, et al. The chronic viral hepatitis as main risk factors of hepatocellular carcinoma development in Yakutia. Siberian Medical J. 2007;22(S2):47–49. (In Russ).
  14. McMahon BJ, Bulkow LR, Singleton RJ, et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology. 2011;54(3):801–807. doi: 10.1002/hep.24442
  15. Mereckiene J, Cotter S, Lopalco P, et al. Hepatitis B immunisation programmes in European Union, Norway and Iceland: Where we were in 2009? Vaccine. 2010;28(28):4470–4477. doi: 10.1016/j.vaccine.2010.04.037
  16. FitzSimons D, McMahon B, Hendrickx G, et al. Burden and prevention of viral hepatitis in the Arctic region, Copenhagen, Denmark, 22–23 March, 2012. Int J Circumpolar Health. 2013;72:21163. doi: 10.3402/ijch.v72i0.21163
  17. Børresen ML, Koch A, Biggar RJ, et al. Effectiveness of the targeted hepatitis B vaccination program in Greenland. Am J Public Health. 2012;102(2):277–284. doi: 10.2105/ajph.2011.300239
  18. WHO. Weekly epidemiological bulletin. July 7, 2017, 92nd year, N 27, 2017, 92, 369–392. Hepatitis B vaccines: WHO position paper, July 2017 [Internet]. Available from: https://www.who.int/wer/2017/pp_hepb_2017_ru.pdf. Accessed: 09.06.2021.
  19. Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003;38(3): 257–265. doi: 10.1016/s0168-8278(02)00413-0
  20. Hamada H, Yatsuhashi H, Yano K, et al. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer. 2002;95(2):331–339. doi: 10.1002/cncr.10662
  21. Kershengoltz BM, Chernobrovkina TV, Kolosova ON. Ethnogenetic features of alcohol resistance in the people of the North. Bulletin of the Northeastern Federal University named after M.K. Ammosov. 2012;9(1):22–28. (In Russ).
  22. Chulanov VP. Epidemiological and clinical significance of genetic heterogeneity of hepatitis A and B viruses [dissertation abstract]. Moscow; 2013. (In Russ). Available from: https://www.crie.ru/pdf/avtoref1(chulanov).pdf.
  23. Zotova AV, Juman AA, Tsikina MN. Significance of viral load determination in hepatits B and C in relatively closed populations of ethnic minorities. The Far Eastern J Infectious Pathology. 2010;16(16):23–26. (In Russ).
  24. Gounder PP, Bulkow LR, Snowball M, et al. Hepatocellular carcinoma risk in Alaska native children and young adults with hepatitis B virus: retrospective cohort analysis. J Pediatr. 2016;178:206–213. doi: 10.1016/j.jpeds.2016.08.017
  25. Livingston SE, Simonetti JP, McMahon BJ, et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis. 2007;195(1):5–11. doi: 10.1086/509894
  26. McMahon BJ, Nolen S, Snowball M, et al. Hepatitis B Virus (HBV) genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for hepatocellular carcinoma: the hepatitis B Alaska (HEP-B-AK) study. Hepatology. 2021. doi: 10.1002/hep.32065

Supplementary files

Supplementary Files
Action
1. Fig. 1. Incidence of acute hepatitis B in the Russian Arctic and the Russian Federation from 1999 to 2019. АЗРФ ― Arctic zone of the Russian Federation; РФ ― Russian Federation.

Download (138KB)
2. Fig. 2. The incidence of chronic forms of hepatitis B (chronic hepatitis B and hepatitis B virus carrier in total) in the Russian Arctic and the Russian Federation in 1999–2019. АЗРФ ― Arctic zone of the Russian Federation; РФ ― Russian Federation.

Download (190KB)
3. Fig. 3. Incidence of chronic forms of hepatitis B (chronic hepatitis B and hepatitis B virus carrier in total) by age groups in the regions of the Russian Arctic, the subarctic regions and the Russian Federation in 2018. АО ― autonomous region; РФ ― Russian Federation.

Download (208KB)
4. Fig. 4. Prevalence of chronic forms of hepatitis B (chronic hepatitis B and hepatitis B virus carrier in total) in the regions of the Russian Arctic, subarctic regions and the Russian Federation by age in 2018. АО ― autonomous region; РФ ― Russian Federation.

Download (208KB)

Copyright (c) 2020 Eco-vector



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies